fell by over 12% in one day, its largest decline since last August. Inspire Medical Systems, which makes an implanted medical device to treat sleep apnea, also fell by nearlyEli Lilly sells tirzepatide under the name Mounjaro for Type 2 Diabetes and Zepbound for obesity.
Patients with severe sleep apnea can have hundreds of episodes in one night, increasing the patient’s risk for high blood pressure, heart disease, and strokes., the lead author of the study and a professor of medicine at the University of California San Diego School of Medicine, said the drug could revolutionize treatment of OSA because it is much more accessible than current machines or device-based interventions, which depend on consistent use.
“It means we can offer an innovative solution, signifying hope and a new standard of care to provide relief to countless individuals and their families,” said Malhotra. “This breakthrough opens the door to a new era of OSA management for people diagnosed with obesity, potentially transforming how we approach and treat this pervasive condition on a global scale.”
Malhotra also said that tirzepatide is beneficial because it targets the root causes of the disorder rather than solely symptoms.According to data from the discount prescription company GoodRx, both Mounjaro and Zepbound cost over $1,000 for a monthly dose.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Herkunft: CNBC - 🏆 12. / 72 Weiterlesen »